|Day Low/High||145.83 / 150.55|
|52 Wk Low/High||108.50 / 194.73|
The firm received a "refusal to file letter" from the FDA regarding the new drug application for Inbrija, a potential treatment for Parkinson's disease.
Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights...
The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.
Vyxeos represents the first new chemotherapy advance in more than 40 years for these adults with AML
Abstract Accepted for Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017
Abstract Accepted for Oral Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017
David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.
Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.
Hikma Granted Right to Sell Authorized Generic of Xyrem in 2023
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, CAA, JAZZ, LFL, MTH, SUM, WYNN Downgrades: REV, TROW, WAGE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Abstracts Accepted for Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017
ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.
Jim Cramer looks for domestic stocks he thinks will benefit from lower taxes and deregulation in the Trump era.
Jim Cramer says the future doesn't look healthy for Fitbit, but he's bullish on Xilinx and T-Mobile.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.